real peptides FAQ

Blood NAD+ elevation doesn't guarantee tissue-level restoration. NAD+ compartmentalization means circulating NAD+ and intracellular NAD+ operate as separate pools. The 2017 Elysium Health trial demonstrated this disconnect: blood NAD+ rose 60% on NR supplementation, but muscle biopsy samples showed no change in NAD+ concentration. Functional outcomes (mitochondrial ATP production, sirtuin activity, DNA repair markers) matter more than blood measurements. If symptoms persist despite elevated blood NAD+, the intervention may not be reaching the tissues driving those symptoms. Liver biopsy or MRS imaging can confirm tissue-level NAD+ status in research settings.

Translation failure from rodent models to human PTSD populations is the single largest risk in peptide research. Rodent fear conditioning is a controlled, single-incident stressor. Human PTSD often involves complex, repeated trauma that alters brain structure beyond receptor density changes. If Selank amidate fails to reduce PTSD symptom severity in Phase II trials, the most likely explanation is pharmacokinetic. Intranasal administration in humans may not achieve the hippocampal concentrations seen in rodent models where direct CNS delivery is possible. Subcutaneous or intravenous routes would need evaluation.

Peptide modifications can sometimes trigger antibody formation, particularly with repeated dosing. If amidate Selank produces anti-drug antibodies, the extended half-life advantage disappears. Antibodies accelerate clearance. No published study has reported immunogenicity with amidate Selank in rodent models, but human immune systems are more variable. Early-phase trials should include antibody titre monitoring at 2, 4, and 12 weeks. If titres rise, standard Selank formulations remain an alternative despite shorter duration.

Reduce the per-administration dose by 50% and extend the escalation timeline. Nasal irritation occurs in approximately 10–15% of research subjects and typically resolves within 5–7 days as the mucosa adapts. Benzyl alcohol in bacteriostatic water can exacerbate irritation. Switching to plain sterile water (with more frequent preparation of smaller batches) eliminates this variable. Headaches occurring within 30–60 minutes of administration suggest transient vasodilation related to rapid BDNF upregulation; this effect diminishes with continued use.

Verify dosing compliance first. MK 677 has a 24-hour half-life and requires daily dosing without gaps to maintain stable plasma levels. If compliance was consistent, the next step is assessing compound purity: peptides synthesized without third-party verification can contain 60–80% active ingredient instead of the expected >98%. Our experience shows that underdosed or impure compounds are the most common cause of non-response. If purity is confirmed, GH resistance due to undiagnosed hypothyroidism or chronic sleep deprivation (<6 hours nightly) blunts IGF-1 response even with functional GH secretagogues. Address the underlying issue before restarting the protocol.

AOD-9604 for weight loss without GLP-1 bypasses gastric slowing entirely. There's no nausea, vomiting, or delayed emptying because the peptide doesn't interact with GLP-1 receptors in the gut or hypothalamus. The trade-off is magnitude: you're targeting lipolysis directly rather than creating a caloric deficit through appetite suppression, so fat loss will be slower and require precise dietary structure. If GI side effects forced you off semaglutide or tirzepatide but you still want peptide-based fat mobilisation, AOD-9604 represents a mechanistically distinct pathway worth exploring in a research context.

Bioavailability drops significantly. Selank's CNS effects depend on direct olfactory transport, which requires intact nasal epithelium. Chronic allergies, rhinitis, or recent nasal trauma all reduce absorption. Subcutaneous or intramuscular routes bypass this issue but have not been studied for BDNF effects. The peptide's pharmacokinetics change entirely when delivered systemically.

This happens more often than most clinicians realize. PCOS and HA can present similarly (irregular or absent periods, low estradiol), but the underlying mechanisms are opposite. PCOS involves high LH-to-FSH ratio and elevated androgens, while HA involves suppressed LH and low androgens. If your 'PCOS' diagnosis was made without measuring LH, FSH, and testosterone levels. Or if you're an athlete or have a history of restrictive eating. You may have been misdiagnosed. A kisspeptin stimulation test can clarify: women with HA will show robust LH release in response to kisspeptin, while true PCOS patients already have high baseline LH and won't respond as dramatically. If you suspect misdiagnosis, request a full reproductive hormone panel (LH, FSH, estradiol, total testosterone, DHEA-S) and discuss kisspeptin testing with a reproductive endocrinologist.

Benzodiazepines lose efficacy over weeks to months because chronic GABA-A receptor activation triggers compensatory downregulation. Selank doesn't activate receptors. It upregulates subunit expression through gene transcription. Mechanistically, this should be less prone to tolerance. However, if chronic Selank administration eventually leads to homeostatic suppression of alpha-2 gene expression, cycling protocols (e.g., 4 weeks on, 2 weeks off) may preserve sensitivity. No long-term tolerance data exist beyond 90-day rodent studies.

You'll miss the inflammatory resolution window where BPC-157 provides its clearest benefit—reducing TNF-alpha and IL-6 by 40–50% in the first 2 weeks—but the proliferative and remodeling phases (where TB-500 and GHK-Cu operate) extend for months, so delayed initiation still targets meaningful biological processes. Start with TB-500 and GHK-Cu only if you're past day 21; BPC-157's primary value diminishes after the acute inflammatory phase resolves.

Switch to a pulsed protocol: administer SS-31 for five consecutive days, then withhold for two days. Continuous daily dosing can suppress endogenous mitochondrial quality control pathways (mitophagy, fission-fusion cycling) because the stabilisation signal from SS-31 reduces the cellular 'need' to replace damaged mitochondria. The two-day break allows baseline mitochondrial turnover to resume while maintaining cumulative SS-31 benefits. Additionally, verify your dosing aligns with your model's metabolic demand. Sedentary models require lower doses than metabolically active or stressed models.

Consider whether ARA-290 is the right research tool for the intended study. The peptide's measurable anti-inflammatory effect on serum biomarkers is most pronounced in subjects with elevated baseline inflammation (hs-CRP 3.0–10.0 mg/L). In subjects with minimal systemic inflammation (hs-CRP <1.0 mg/L), the peptide may still exert tissue-protective and neuroprotective effects at the cellular level, but these won't manifest as dramatic reductions in circulating inflammatory markers. If tissue-level outcomes (wound healing, neuropathic pain reduction) are the primary endpoints, proceed with the protocol but adjust expectations for biomarker changes. Focus on clinical endpoints rather than lab deltas.

Stop the protocol immediately and investigate the cause. ARA-290 selectively binds the innate repair receptor and should NOT stimulate erythropoiesis. Any hemoglobin elevation above 1.0 g/dL from baseline suggests either peptide contamination with trace erythropoietic EPO or an unrelated hematological process. Send a sample of the reconstituted peptide for third-party purity analysis to confirm it contains no full-length EPO contamination. If the peptide tests clean, refer the subject for hematological evaluation to rule out polycythemia vera, chronic hypoxia, or other causes of secondary erythrocytosis. Do not resume ARA-290 administration until the source of hemoglobin elevation is identified.

Refrigerate immediately but do not use the peptide for critical protocols. Request a replacement from the supplier and document the temperature excursion. Even brief exposure to 25–30°C initiates irreversible denaturation. The peptide may dissolve normally when reconstituted but will deliver unpredictable or absent bioactivity. Cold-chain breaches during shipping are the supplier's responsibility to prevent through insulated packaging and temperature monitoring. Real Peptides ships all peptides with gel packs and insulated liners to maintain sub-8°C temperatures during ground transit.

Lyophilized peptides (the powdered form) are stable at room temperature for short periods, but once reconstituted with bacteriostatic water, temperature excursions above 8°C cause irreversible protein denaturation. BPC-157 and TB-500 are particularly susceptible—a single 24-hour period at 15–20°C can reduce potency by 30–50%, and you won't detect the loss visually. If you're traveling or lack consistent refrigeration, reconstitute only 7 days' worth at a time and use a medical-grade cooler that maintains 2–8°C without ice packs.

Reduce frequency to once daily or dilute the solution with sterile saline (1:1 ratio). Nasal irritation occurs in approximately 15% of users at standard concentration, typically resolving within 7–10 days as mucosal tolerance develops. If bleeding occurs, discontinue intranasal use. Subcutaneous administration is theoretically viable but lacks published safety data in TBI populations. Consult a research physician before switching routes.

Most likely, yes. Unless you've addressed the underlying metabolic or psychological stressors that caused HA in the first place. Kisspeptin studied hypothalamic amenorrhea trials tracked participants for 6 months after stopping treatment, and 70% reverted to amenorrhea within 3 months if they hadn't gained weight or reduced training volume. Kisspeptin doesn't 'cure' HA; it temporarily overrides the suppression. For sustained recovery, you need leptin levels above the threshold (typically requiring body fat percentage >20–22% and stable caloric intake), cortisol normalization (often requiring stress management or therapy), and realistic exercise volume. If you achieve pregnancy on kisspeptin, the hormonal milieu of pregnancy itself often resets the reproductive axis. Many women who conceive via kisspeptin or other interventions regain spontaneous cycles postpartum even if they don't fully restore weight.

Confirm your model actually has cardiolipin-mediated mitochondrial dysfunction. SS-31 binds cardiolipin at the inner mitochondrial membrane to stabilise cristae and reduce electron leak. If your model has healthy mitochondria with low baseline ROS, there may be no dysfunction for SS-31 to correct. Induce mild oxidative stress (100–200 µM H2O2 for 1–2 hours) or use a hypoxia-reoxygenation protocol to create measurable mitochondrial membrane disruption, then re-test SS-31 efficacy.

Minoxidil works by extending anagen phase through increased blood flow and potassium channel activation. It doesn't repair basement membrane anchorage. If your response has plateaued after 2–3 years, it's likely because follicle miniaturization has progressed to the point where stem cell depletion limits further growth regardless of vascular support. Adding AHK-Cu targets the structural deficiency minoxidil doesn't address, potentially reactivating dormant follicles that minoxidil alone can't rescue.

Tesofensine's mechanism avoids gastric involvement entirely. There is no delayed emptying, no prolonged satiety signal requiring the gut to stay full longer, and no activation of brainstem emetic pathways that cause nausea with GLP-1 therapy. Phase 2 data showed nausea rates below 5% across all tesofensine dose groups, statistically indistinguishable from placebo. The compound remains investigational, but for researchers exploring alternatives to incretin-based weight loss in populations with documented GLP-1 intolerance, tesofensine represents the only non-incretin mechanism with clinical evidence exceeding 10% body weight reduction.